In the battle against migraine, is the missing link outside of the brain?
By Charlie Culverhouse in Insight
The migraine market, on the surface, seems relatively well-served. It’s considered fast-moving, with a sizeable pipeline of treatments, including drugs with novel pharmaceutical mechanisms, and non-pharmacological treatments too. The EU migraine market was worth 3.8bn as of 2023, and it’s predicted to continue to grow. Pharmaceutical treatment is currently…